Colorectal Cancer Clinical Trials in Raleigh, NC

Colorectal Cancer Clinical Trials in Raleigh, NC

View the best 10 colorectal cancer medical studies in Raleigh, North Carolina. Access promising new therapies by applying to a Raleigh-based Colorectal Cancer clinical trial.

Trials in Raleigh, North Carolina

Here are the top 10 medical studies for colorectal cancer in Raleigh, North Carolina

Image of GSK Investigational Site in Tucson, United States.

Dostarlimab +2 More

PD-1 Inhibitor

Recruiting2 awardsPhase 3
This trial is testing dostarlimab, a drug that helps the immune system fight cancer. It targets patients with a specific type of colon cancer that has certain genetic features and can be surgically removed. Dostarlimab works by helping the immune system recognize and destroy cancer cells.
Image of IU Simon Cancer Center in Indianapolis, United States.

Irinotecan

Alkylating agents

Recruiting1 awardPhase 2
This trial is testing a new way to give colon cancer patients a standard combination chemotherapy treatment, which includes the anti-cancer drugs 5-Fluorouracil (5FU), leucovorin and irinotecan (known as FOLFIRI), plus the anti-angiogenesis drug bevacizumab (Avastin). The study is designed to test the FOLFIRI regimen based on certain characteristics of a person's genetic makeup or "genes".
Image of Mayo Clinic Arizona in Phoenix, United States.

Tucatinib +5 More

Small Molecule Kinase Inhibitor

Recruiting1 awardPhase 1 & 2
This trial will study whether tucatinib is safe when given with other anti-cancer drugs to treat gastrointestinal cancer.
Image of Duke Cancer Institute in Durham, United States.

mHealth Coping Skills Training for Symptom Management (mCOPE)

Behavioral Intervention

Recruiting1 award4 criteria
This trial is testing whether an app can help young and middle-aged colorectal cancer patients with pain, fatigue, and distress. The app would teach patients coping skills and provide personalized real-time feedback.
Image of Mayo Clinic in Arizona in Scottsdale, United States.

Panitumumab +2 More

Monoclonal Antibodies

Recruiting1 awardPhase 2
This trial is comparing panitumumab to the standard of care for treating patients with colorectal cancer that has spread and is negative for RAS wild-type.
Image of Sarah Cannon Research Institute - CO in Denver, United States.

ST316

WNT/β-catenin signaling pathway inhibitor

Recruiting1 awardPhase 1
This trial tests a new cancer drug to find if it's safe, how it works, and if it's effective against advanced solid tumors.
Image of Cedars-Sinai Medical Center in Los Angeles, United States.

RGX-202-01 +1 More

Small Molecule Inhibitor

Recruiting1 awardPhase 1
This trial is testing a new drug, RGX-202-01, to see if it can shrink tumors in people with gastrointestinal cancer. The study will test different doses of the drug to see what is safe and effective. The study will also test the drug in combination with other drugs that are commonly used to treat gastrointestinal cancer.
Image of Moffitt Cancer Center in Tampa, United States.

Panitumumab +2 More

Monoclonal Antibodies

Recruiting1 awardPhase 2
This trial will test a new combination of cancer drugs to see if it is effective in treating subjects with metastatic colorectal cancer who have not responded to other treatments.
Image of USC Norris Comprehensive Cancer Center in Los Angeles, United States.

PC14586 +1 More

Small Molecule

Recruiting1 awardPhase 1 & 2
This trial is testing a new oral drug, PC14586 (rezatapopt), alone and with pembrolizumab, in patients with advanced cancers that have a specific genetic mutation. The drug aims to fix a mutated protein to help control cancer growth. The study will determine the best dose and evaluate the drug's safety and effectiveness.
Image of City of Hope National Medical Center in Duarte, United States.

Sotorasib +1 More

Small Molecule Drug

Recruiting2 awardsPhase 3
This trial is testing two doses of sotorasib combined with panitumumab in patients with a specific type of colorectal cancer that has not responded to other treatments. Sotorasib targets a genetic mutation in the cancer cells, while panitumumab helps the immune system attack the cancer. The goal is to see if this combination can help patients live longer without their cancer getting worse.

Phase 3 Trials

Trials With No Placebo

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.